Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Candel Therapeutics, Inc.CADL · Entity 4969 | Director | June 23, 2026 | June 24, 2026 |
| ESTABLISHMENT LABS HOLDINGS INC.ESTA · Entity 4473 | Chief Financial Officer | May 20, 2021 | May 21, 2021 |
| Outset Medical, Inc.OM · Entity 7026 | Chief Financial Officer | August 17, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Candel Therapeutics, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08 · Expires 2036-06-23 | Direct | 32,000 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 32,000 · Balance 32,000 F1: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.
ESTABLISHMENT LABS HOLDINGS INC.
Report date May 20, 2021 · Filed May 21, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-05-21 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2021-05-20 · Exercise / conversion · Acquired 6,260 · Balance 6,260 F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Row 2 · 2021-05-20 · Sale · Disposed 6,260 · Balance 0 F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2: This transaction was executed in multiple trades at prices ranging from $74.00 to $74.91 per share. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Row 3 · 2021-05-21 · Exercise / conversion · Acquired 2,840 · Balance 2,840 F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Row 4 · 2021-05-21 · Sale · Disposed 694 · Balance 2,146 F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3: This transaction was executed in multiple trades at prices ranging from $74.00 to $74.94 per share. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Row 5 · 2021-05-21 · Sale · Disposed 1,958 · Balance 188 F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4: This transaction was executed in multiple trades at prices ranging from $75.00 to $75.91 per share. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Row 6 · 2021-05-21 · Sale · Disposed 188 · Balance 0 F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5: This transaction was executed in multiple trades at prices ranging from $76.00 to $76.11 per share. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.19 · Expires 2028-03-13 | Direct | 139,960 |
Reported balance
After 2021-05-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-05-20 · Exercise / conversion · Disposed 6,260 · Balance 139,960 F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6: The option, originally for 147,120 shares, vested as to one-fourth of the shares on July 1, 2018, and one-fourth of the shares subject to the option vest each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.19 · Expires 2028-03-13 | Direct | 137,120 |
Reported balance
After 2021-05-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-05-21 · Exercise / conversion · Disposed 2,840 · Balance 137,120 F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6: The option, originally for 147,120 shares, vested as to one-fourth of the shares on July 1, 2018, and one-fourth of the shares subject to the option vest each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
F2: This transaction was executed in multiple trades at prices ranging from $74.00 to $74.91 per share. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: This transaction was executed in multiple trades at prices ranging from $74.00 to $74.94 per share. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4: This transaction was executed in multiple trades at prices ranging from $75.00 to $75.91 per share. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F5: This transaction was executed in multiple trades at prices ranging from $76.00 to $76.11 per share. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F6: The option, originally for 147,120 shares, vested as to one-fourth of the shares on July 1, 2018, and one-fourth of the shares subject to the option vest each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date.
Outset Medical, Inc.
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 180,840 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Sale · Disposed 4,543 · Balance 180,840 F1: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of an aggregate of 12,322 shares of Common Stock underlying RSUs granted to the reporting person on June 10, 2025. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of an aggregate of 12,322 shares of Common Stock underlying RSUs granted to the reporting person on June 10, 2025. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SeaSpine Holdings Corp
Report date January 05, 2023 · Filed January 10, 2023
Section 16 reporting ended · disclosed 2023-01-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-01-05 transaction · row 1
1 source rowRow 1 · 2023-01-05 · Disposition to issuer · Disposed 36,056 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, SeaSpine Holdings Corporation, which became effective on January 5, 2023, in exchange for 15,010 Orthofix Medical Inc. ("Orthofix") ordinary shares having a market value of $22.76 per share at the effective time of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, SeaSpine Holdings Corporation, which became effective on January 5, 2023, in exchange for 15,010 Orthofix Medical Inc. ("Orthofix") ordinary shares having a market value of $22.76 per share at the effective time of the merger.
Shockwave Medical, Inc.
Report date May 31, 2024 · Filed May 31, 2024
Section 16 reporting ended · disclosed 2024-05-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 1
1 source rowRow 1 · 2024-05-31 · Disposition to issuer · Disposed 19,890 · Balance 0 F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"),
F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 18, 2026 22:46 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 4,543 | $4.39 | $19,943.77 |
DisclosureSEC source: 0001484612-26-000047 · edgardoc.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,840 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of an aggregate of 12,322 shares of Common Stock underlying RSUs granted to the reporting person on June 10, 2025. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 26, 2026 Filed Jun 29, 2026 23:15 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantCommon Stock | 71,630 | $0.00 | $0.00 |
DisclosureSEC source: 0001484612-26-000043 · edgardoc.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,383 F1 · shares: Represents restricted stock units ("RSU") granted to the reporting person on June 26, 2026. Each RSU represents a contingent right to receive one share of common stock. These RSUs shall vest 33.33% on June 26, 2027, and the remaining 66.67% shall vest in equal installments over the course of the following two years on a quarterly basis on February 15th, May 15th, August 15th and November 15th, subject to the reporting person's continuous service through the applicable vesting date. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 20:30 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001742428-26-000004 · ownership.xml · derivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 22:07 UTC | Outset Medical, Inc. OM · Entity 7026 | SaleCommon Stock | 17,672 | $4.94 | $87,299.68 |
DisclosureSEC source: 0001484612-26-000029 · edgardoc.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,753 F1 · shares: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of an aggregate of 32,856 shares of Common Stock underlying RSUs granted to the reporting person on June 10, 2025. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 12:37 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $4.94 | $0.00 |
DisclosureSEC source: 0000950170-25-087705 · ownership.xml · derivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2035-06-17 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 21:30 UTC | Outset Medical, Inc. OM · Entity 7026 | GrantCommon Stock | 131,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001484612-25-000059 · edgardoc.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,425 F1 · shares: Represents restricted stock units ("RSU") granted to the reporting person on June 10,2025. Each RSU represents a contingent right to receive one share of common stock. These RSUs shall vest 33.33% on June 3, 2026, and the remaining 66.67% shall vest in equal installments over the course of the following two years on a quarterly basis on each February 15th, May 15th, August 15th and November 15th, subject to the reporting person's continuous service through the applicable vesting date. Read SEC document |
| June 26, 2024 Filed Jun 27, 2024 12:35 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0000950170-24-078169 · ownership.xml · derivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2034-06-26 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 26, 2025 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| May 31, 2024 Filed May 31, 2024 20:27 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Disposition to issuerCommon Stock | 19,890 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001642545-24-000112 · wk-form4_1717187260.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2 · price: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 01:18 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 19,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001642545-24-000038 · wk-form4_1707268707.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,890 Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 13:00 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001209191-23-040136 · doc4.xml · derivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2033-06-28 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 28, 2024 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| January 05, 2023 Filed Jan 10, 2023 00:20 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | Disposition to issuerCommon Stock | 36,056 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001637761-23-000043 · wf-form4_167330999970775.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to the Agreement and Plan of Merger by and among the issuer, SeaSpine Holdings Corporation, which became effective on January 5, 2023, in exchange for 15,010 Orthofix Medical Inc. ("Orthofix") ordinary shares having a market value of $22.76 per share at the effective time of the merger. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 12:05 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 28,480 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0000899243-22-028203 · doc4.xml · derivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,480 Underlying: Common Stock · 28,480 shares Expires 2032-08-08 F1 · derivative.exercise_date: 33% of the shares underlying this option shall vest and become exercisable on August 8, 2023, with the remainder vesting in two (2) equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 21:24 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | GrantCommon Stock | 15,943 | $0.00 | $0.00 |
DisclosureSEC source: 0001637761-22-000095 · wf-form4_165429142776126.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,056 F1 · shares: The restricted stock award vests in full on June 1, 2023, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. Read SEC document |
| March 14, 2022 Filed Mar 15, 2022 20:06 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | SaleCommon Stock | 2,000 | $12.03 | $24,060.00 |
DisclosureSEC source: 0001637761-22-000059 · wf-form4_164737476871242.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,113 F1 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $11.76 to not more than $12.37. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The transaction reported was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 23:31 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | SaleCommon Stock | 2,000 | $12.06 | $24,120.00 |
DisclosureSEC source: 0001637761-22-000034 · wf-form4_164505426773148.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,113 F1 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $12.05 to not more than $12.09. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The transaction reported was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| January 10, 2022 Filed Jan 10, 2022 22:23 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | SaleCommon Stock | 2,000 | $12.35 | $24,700.00 |
DisclosureSEC source: 0001637761-22-000018 · wf-form4_164185338437029.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,113 F1 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $12.12 to not more than $12.72. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The transaction reported was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 23:07 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | GrantCommon Stock | 609 | $0.00 | $0.00 |
DisclosureSEC source: 0001637761-21-000149 · wf-form4_162526722610379.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,113 F1 · shares: This restricted stock award was issued to the Reporting Person pursuant to her election under the issuer's director compensation program to receive such award in lieu of a portion of the cash retainer the Reporting Person is entitled to receive in her capacity as a non-employee director of the issuer. The restricted stock award vests immediately on the date of grant. The number of shares was calculated by dividing the portion of the retainer the Reporting Person elected not to receive in cash by the closing price of the issuer's common stock on the last trading day of the quarter. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:17 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | GrantCommon Stock | 6,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001637761-21-000129 · wf-form4_162283780859907.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,504 F1 · shares: The restricted stock award vests in full on June 2, 2022, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation ("SeaSpine") at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. Read SEC document |
| May 21, 2021 Filed May 21, 2021 21:37 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | Exercise / conversionStock Option (Right to buy) · Derivative | 2,840 | $10.19 Strike: $10.19 | $28,939.60 |
DisclosureSEC source: 0001742428-21-000003 · wf-form4_162163303133381.xml · derivative · entry 8 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,120 Underlying: Common Shares · 2,840 shares Expires 2028-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · derivative.exercise_date: The option, originally for 147,120 shares, vested as to one-fourth of the shares on July 1, 2018, and one-fourth of the shares subject to the option vest each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 21, 2021 Filed May 21, 2021 21:37 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | SaleCommon Shares | 188 | $76.07 | $14,300.26 |
DisclosureSEC source: 0001742428-21-000003 · wf-form4_162163303133381.xml · nonDerivative · entry 6 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $76.00 to $76.11 per share. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 21, 2021 Filed May 21, 2021 21:37 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | SaleCommon Shares | 1,958 | $75.35 | $147,530.01 |
DisclosureSEC source: 0001742428-21-000003 · wf-form4_162163303133381.xml · nonDerivative · entry 5 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $75.00 to $75.91 per share. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 21, 2021 Filed May 21, 2021 21:37 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | SaleCommon Shares | 694 | $74.73 | $51,860.68 |
DisclosureSEC source: 0001742428-21-000003 · wf-form4_162163303133381.xml · nonDerivative · entry 4 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,146 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $74.00 to $74.94 per share. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 21, 2021 Filed May 21, 2021 21:37 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | Exercise / conversionCommon Shares | 2,840 | $10.19 | $28,939.60 |
DisclosureSEC source: 0001742428-21-000003 · wf-form4_162163303133381.xml · nonDerivative · entry 3 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 20, 2021 Filed May 21, 2021 21:37 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | Exercise / conversionStock Option (Right to buy) · Derivative | 6,260 | $10.19 Strike: $10.19 | $63,789.40 |
DisclosureSEC source: 0001742428-21-000003 · wf-form4_162163303133381.xml · derivative · entry 7 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,960 Underlying: Common Shares · 6,260 shares Expires 2028-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · derivative.exercise_date: The option, originally for 147,120 shares, vested as to one-fourth of the shares on July 1, 2018, and one-fourth of the shares subject to the option vest each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 20, 2021 Filed May 21, 2021 21:37 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | SaleCommon Shares | 6,260 | $74.37 | $465,569.97 |
DisclosureSEC source: 0001742428-21-000003 · wf-form4_162163303133381.xml · nonDerivative · entry 2 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $74.00 to $74.91 per share. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 20, 2021 Filed May 21, 2021 21:37 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | Exercise / conversionCommon Shares | 6,260 | $10.19 | $63,789.40 |
DisclosureSEC source: 0001742428-21-000003 · wf-form4_162163303133381.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 19, 2021 Filed May 20, 2021 21:23 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | Exercise / conversionStock Option (Right to buy) · Derivative | 800 | $10.19 Strike: $10.19 | $8,152.00 |
DisclosureSEC source: 0001742428-21-000002 · wf-form4_162154580686068.xml · derivative · entry 6 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,220 Underlying: Common Shares · 800 shares Expires 2028-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · derivative.exercise_date: The option, originally for 147,120 shares, vested as to one-fourth of the shares on July 1, 2018, and one-fourth of the shares subject to the option vest each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 19, 2021 Filed May 20, 2021 21:23 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | SaleCommon Shares | 800 | $74.31 | $59,444.48 |
DisclosureSEC source: 0001742428-21-000002 · wf-form4_162154580686068.xml · nonDerivative · entry 4 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $74.00 to $74.61 per share. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 19, 2021 Filed May 20, 2021 21:23 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | Exercise / conversionCommon Shares | 800 | $10.19 | $8,152.00 |
DisclosureSEC source: 0001742428-21-000002 · wf-form4_162154580686068.xml · nonDerivative · entry 3 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:23 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | Exercise / conversionStock Option (Right to buy) · Derivative | 100 | $10.19 Strike: $10.19 | $1,019.00 |
DisclosureSEC source: 0001742428-21-000002 · wf-form4_162154580686068.xml · derivative · entry 5 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,020 Underlying: Common Shares · 100 shares Expires 2028-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · derivative.exercise_date: The option, originally for 147,120 shares, vested as to one-fourth of the shares on July 1, 2018, and one-fourth of the shares subject to the option vest each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:23 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | SaleCommon Shares | 100 | $74.00 | $7,400.00 |
DisclosureSEC source: 0001742428-21-000002 · wf-form4_162154580686068.xml · nonDerivative · entry 2 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| May 18, 2021 Filed May 20, 2021 21:23 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | Exercise / conversionCommon Shares | 100 | $10.19 | $1,019.00 |
DisclosureSEC source: 0001742428-21-000002 · wf-form4_162154580686068.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 23:27 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | GrantCommon Stock | 718 | $0.00 | $0.00 |
DisclosureSEC source: 0001637761-21-000072 · wf-form4_161731958688550.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,251 F1 · shares: This restricted stock award was issued to the Reporting Person pursuant to her election under the issuer's director compensation program to receive such award in lieu of a portion of the cash retainer the Reporting Person is entitled to receive in her capacity as a non-employee director of the issuer. The restricted stock award vests immediately on the date of grant. The number of shares was calculated by dividing the portion of the retainer the Reporting Person elected not to receive in cash by the closing price of the issuer's common stock on the last trading day of the quarter. Read SEC document |
| March 08, 2021 Filed Mar 8, 2021 21:05 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | SaleCommon Stock | 2,920 | $18.28 | $53,377.60 |
DisclosureSEC source: 0001637761-21-000058 · wf-form4_161523752227131.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,533 F1 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $18.27 to not more than $18.35. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The transaction reported was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 21:16 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | SaleCommon Stock | 3,000 | $17.76 | $53,280.00 |
DisclosureSEC source: 0001637761-21-000048 · wf-form4_161411493752143.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,453 F1 · price: The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from not less than $17.70 to not more than $17.91. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The transaction reported was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:31 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | GrantStock Option (Right to buy) · Derivative | 12,401 | $0.00 Strike: $69.49 | $0.00 |
DisclosureSEC source: 0001742428-21-000001 · wf-form4_161359744123497.xml · derivative · entry 1 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,401 Underlying: Common Shares · 12,401 shares Expires 2031-02-15 F1 · derivative.exercise_date: One-fourth of the shares subject to the option shall vest on February 15, 2022 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 21:07 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | GrantCommon Stock | 716 | $0.00 | $0.00 |
DisclosureSEC source: 0001637761-21-000008 · wf-form4_160979442455152.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,453 F1 · shares: This restricted stock award was issued to the Reporting Person pursuant to her election under the issuer's director compensation program to receive such award in lieu of a portion of the cash retainer the Reporting Person is entitled to receive in her capacity as a non-employee director of the issuer. The restricted stock award vests immediately on the date of grant. The number of shares was calculated by dividing the portion of the retainer the Reporting Person elected not to receive in cash by the closing price of the issuer's common stock on the last trading day of the quarter. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 23:50 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | GrantCommon Stock | 874 | $0.00 | $0.00 |
DisclosureSEC source: 0001637761-20-000129 · wf-form4_160159622024683.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,737 F1 · shares: This restricted stock award was issued to the Reporting Person pursuant to her election under the issuer's director compensation program to receive such award in lieu of a portion of the cash retainer the Reporting Person is entitled to receive in her capacity as a non-employee director of the issuer. The restricted stock award vests immediately on the date of grant. The number of shares was calculated by dividing the portion of the retainer the Reporting Person elected not to receive in cash by the closing price of the issuer's common stock on the last trading day of the quarter. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:08 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | GrantCommon Stock | 1,193 | $0.00 | $0.00 |
DisclosureSEC source: 0001637761-20-000089 · wf-form4_159372043550189.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,863 F1 · shares: This restricted stock award was issued to the Reporting Person pursuant to her election under the issuer's director compensation program to receive such award in lieu of a portion of the cash retainer the Reporting Person is entitled to receive in her capacity as a non-employee director of the issuer. The restricted stock award vests immediately on the date of grant. The number of shares was calculated by dividing the portion of the retainer the Reporting Person elected not to receive in cash by the closing price of the issuer's common stock on the last trading day of the quarter. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 20:37 UTC | ESTABLISHMENT LABS HOLDINGS INC. ESTA · Entity 4473 | GrantStock Option (Right to buy) · Derivative | 35,000 | $0.00 Strike: $17.03 | $0.00 |
DisclosureSEC source: 0001628280-20-010072 · wf-form4_159354942787716.xml · derivative · entry 1 Gaeta Renee · CIK 0001742428 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Shares · 35,000 shares Expires 2030-06-26 F1 · derivative.exercise_date: One-fourth of the shares subject to the option shall vest on June 26, 2021 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 23:41 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | GrantCommon Stock | 8,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001637761-20-000073 · wf-form4_159140046105320.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,670 F1 · shares: The restricted stock award vests in full on June 3, 2021, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation ("SeaSpine") at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:15 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | GrantCommon Stock | 7,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001637761-19-000081 · wf-form4_155933370879567.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,182 F1 · shares: The restricted stock award vests in full on May 29, 2020, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation ("SeaSpine") at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 22:54 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | GrantCommon Stock | 5,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001637761-19-000027 · wf-form4_155070323350756.xml · nonDerivative · entry 1 Gaeta Renee · CIK 0001742428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,920 F1 · shares: The restricted stock award vests in full on February 19, 2020, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.